Markets Stifel cuts Vanda Pharma to hold; PT to $17 from $26 Stifel downgraded Vanda Pharmaceuticals (NASDAQ:VNDA) to “hold” from “buy” and cut its price target to $17 from $26 after a deeper look into a FDA lawsuit against the company, its pipeline and execution risk. The stock... July 25, 2019